05:48 PM EST, 12/19/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield "meaningful" cost savings based on the results of a budget impact analysis.

The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.

A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.